TrialJAMA dermatology2023

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.

Matthew J Zirwas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.